EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety of Streptococcus pyogenes Vaccines: Anticipating and Overcoming Challenges for Clinical Trials and Post-Marketing Monitoring

Edwin J Asturias, Jean-Louis Excler iD, James Ackland, Marco Cavaleri, Alma Fulurija, Raj Long, Mignon McCulloch, Shiranee Sriskandan, Wellington Sun, Liesl Zühlke iD, Jerome H Kim, James B Dale und 1 weitere

Clinical Infectious Diseases · 18.09.2023 · 77 (6) · 917-924

DOI: 10.1093/cid/ciad311 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 26.05.2023. Verfasst von Edwin J Asturias und 12 weiteren Autor:innen. Beteiligte Einrichtung: Colorado School of Public Health, University of Colorado, Aurora Colorado, USA. Hauptthemen laut MEDLINE: Streptococcal Infections, Streptococcal Vaccines. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Streptococcus pyogenes (Strep A) infections result in a vastly underestimated burden of acute and chronic disease globally. The Strep A Vaccine Global Consortium’s (SAVAC’s) mission is to accelerate the development of safe, effective, and affordable S. pyogenes vaccines. The safety of vaccine recipients is of paramount importance. A single S. pyogenes vaccine clinical trial conducted in the 1960s raised important safety concerns. A SAVAC Safety Working Group was established to review the safety assessment methodology and results of more recent early-phase clinical trials and to consider future challenges for vaccine safety assessments across all phases of vaccine development. No clinical or biological safety signals were detected in any of these early-phase trials in the modern era. Improvements in vaccine safety assessments need further consideration, particularly for pediatric clinical trials, large-scale efficacy trials, and preparation for post-marketing pharmacovigilance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Streptococcal InfectionsStreptococcal VaccinesChildHumansStreptococcus pyogenesClinical Trials as Topic

Stichwörter der Autor:innen

Streptococcus pyogenesacute rheumatic feverclinical trialsafetyvaccine

Substanzen

Streptococcal Vaccines

Autor:innen und Institutionen

  • Colorado School of Public Health, University of Colorado, Aurora Colorado, USA.
  • Children's Hospital, Anschutz Medical Campus, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Director General's Office, International Vaccine Institute, Seoul, Republic of Korea.
  • Global BioSolutions, Melbourne, Australia.
  • Anti-Infectives and Vaccines, European Medicines Agency, Amsterdam, The Netherlands.
  • Group A Streptococcal and Rheumatic Heart Disease Team, Telethon Kids Institute, Perth, Australia.

ORCID-Profile: Jean-Louis Excler, Liesl Zühlke

Förderung

  • Wellcome Trust

Zitieren

APA

Asturias, E. J., Excler, J. L., Ackland, J., Cavaleri, M., Fulurija, A., Long, R., McCulloch, M., Sriskandan, S., Sun, W., Zühlke, L., Kim, J. H., Dale, J. B., & Steer, A. C. (2023). Safety of Streptococcus pyogenes Vaccines: Anticipating and Overcoming Challenges for Clinical Trials and Post-Marketing Monitoring. Clinical Infectious Diseases, 77(6), 917-924. https://doi.org/10.1093/cid/ciad311

Vancouver

Asturias EJ, Excler JL, Ackland J, Cavaleri M, Fulurija A, Long R, et al. Safety of Streptococcus pyogenes Vaccines: Anticipating and Overcoming Challenges for Clinical Trials and Post-Marketing Monitoring. Clinical Infectious Diseases. 2023;77(6):917-924. doi:10.1093/cid/ciad311

BibTeX
@article{Asturias2023,
  author = {Asturias, Edwin J and Excler, Jean-Louis and Ackland, James and Cavaleri, Marco and Fulurija, Alma and Long, Raj and McCulloch, Mignon and Sriskandan, Shiranee and Sun, Wellington and Zühlke, Liesl and Kim, Jerome H and Dale, James B and Steer, Andrew C},
  title = {Safety of Streptococcus pyogenes Vaccines: Anticipating and Overcoming Challenges for Clinical Trials and Post-Marketing Monitoring},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  volume = {77},
  number = {6},
  pages = {917--924},
  doi = {10.1093/cid/ciad311}
}
Kostenlos starten →